

Iterum on deck for IPO of upto \$92 M

03 May 2018 | News

The clinical-stage pharma company is focused on developing an antibiotic called sulopenem that it licensed from Pfizer in late 2015.



Singapore- Dublin, Ireland-domiciled Iterum Therapeutics (ITRM) has filed a preliminary prospectus for its U.S. IPO.

The clinical-stage pharma company is focused on developing an antibiotic called sulopenem that it licensed from Pfizer in late 2015. The company says there are two main opportunities for the ß-lactam antibiotic: patients in a community setting with uncomplicated urinary tract infections at elevated risk of treatment failure and hospitalized patients with complicated antibiotic-resistant infections.